Related Experiment Video
Updated: Jun 27, 2026
05:44
Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis
Published on: October 13, 2023
Multiple sclerosis: etiology and treatment strategies
Michael Namaka1, Dana Turcotte, Christine Leong
1Faculty of Pharmacy and Neurology, University of Manitoba, Health Sciences Centre, Winnipeg, Manitoba, Canada. namakamp@ms.umanitoba.ca
Summary
Multiple sclerosis (MS) research shows no cure yet, but treatments can slow disease progression and manage symptoms. An interprofessional healthcare team is crucial for navigating life with MS.
Area of Science:
- Neurology
- Immunology
Background:
- Multiple sclerosis (MS) is a complex neurological disease with varied patient presentations.
- Diagnosis and symptom management in MS are challenging due to its heterogeneous nature.
Purpose of the Study:
- To review the underlying causes (etiology) of multiple sclerosis (MS).
- To explore current and emerging treatment strategies for managing MS and its symptoms.
Main Methods:
- A comprehensive literature review of published studies on MS and its treatments from 1955 onwards.
- Utilized search terms including "multiple sclerosis," "pathology," "prevalence," "genetics," and common MS symptoms.
- Reviewed 72 studies employing level 1, 2, and 3 evidence-based search strategies, prioritizing large, randomized controlled trials.
Main Results:
- Multiple sclerosis (MS) exhibits significant variability in its impact on individual patients.
- Effective management of MS symptoms necessitates a collaborative, interprofessional team approach.
Conclusions:
- Currently, there is no definitive cure for multiple sclerosis (MS).
- Available treatments primarily focus on slowing disease progression and alleviating symptoms.
- An interprofessional healthcare team is vital for supporting patients throughout their journey with MS.
More Related Videos
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...